Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency, Chronic 1

Interventions

Magnetic Resonance Spectroscopy 284Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 224Nivolumab 182Cisplatin 172Biopsy 163Carboplatin 152Radiosurgery 139fludarabine 128Blood Specimen Collection 128Surveys and Questionnaires 117Gemcitabine 117Paclitaxel 114Standard of Care 110venetoclax 109Dexamethasone 103Bevacizumab 96Radiation 92Rituximab 89Oxaliplatin 86Capecitabine 86Cytarabine 85Drug Therapy 83Ipilimumab 81Doxorubicin 81durvalumab 80atezolizumab 74fludarabine phosphate 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Quillaja Saponins × 90 days × Clear all
NCT06741072 2026-04-21

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Ohio State University Comprehensive Cancer Center

Phase 1 Suspended
55 enrolled

Renal Insufficiency, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡